Gastroesophageal Junction (GEJ) Cancers
In recent years, treatment options for advanced gastric cancer have been limited. But now, with the introduction of Satri-Cel CAR T Cell Therapy (Satricabtagene Autoleucel – CT041), the landscape of gastric cancer treatment is rapidly evolving.
At the ASCO 2025 Annual Meeting, groundbreaking data on this therapy’s success was presented. Satri-Cel, a targeted CAR T therapy against Claudin 18.2 (CLDN18.2), offers new hope to patients with treatment-resistant advanced gastric and gastroesophageal junction (GEJ) cancers.
What Is Satri-Cel CAR T Therapy?
Satri-Cel is an advanced cellular immunotherapy where a patient’s own T cells are genetically engineered to express CARs (chimeric antigen receptors) that specifically recognize and attack tumor cells expressing the Claudin 18.2 (CLDN18.2) protein.
This protein is highly expressed in approximately 70% of gastric cancers, making it an ideal and selective target for therapy.
Key Results from the CT041 Study Presented at ASCO 2025
Study Design:
156 patients with advanced gastric and GEJ cancer
All patients were resistant to at least two prior lines of therapy
Randomized 2:1 (two patients received Satri-Cel, one received treatment of physician’s choice [TPC])
Main Outcomes:
Progression-Free Survival (PFS): 5.6 months with Satri-Cel vs. 2.9 months with TPC
Overall Survival (OS): 12.8 months with Satri-Cel vs. 5.5 months with TPC
Objective Response Rate (ORR): 57.1%, with several complete responses (CR) reported
Safety: Cytokine release syndrome (CRS) was the most common adverse event, mostly low-grade and manageable
Why Is Claudin 18.2 an Ideal Therapeutic Target?
Highly overexpressed in gastric and GEJ tumors
Limited expression in healthy non-gastric tissues
Lower risk of off-target toxicity
Less resistance compared to conventional therapies
China Leads the Way in CAR T Therapy for Solid Tumors
China has emerged as a global leader in the development of CAR T cell therapies for solid tumors thanks to its advanced research infrastructure and supportive regulatory environment.
Carsgen Therapeutics, a pioneering Chinese biotech, is currently conducting over 10 active trials on Claudin 18.2 CAR T Therapy across various cancers, including gastric, pancreatic, and other GI malignancies.
The Future of Satri-Cel in Gastric Cancer Treatment
Global Expansion of Satri-Cel:
Active trials in the United States (under FDA IND)
Ongoing trials in Europe and other Asian countries (Japan, South Korea)
Goal: To become the standard second-line or even first-line therapy for CLDN18.2-positive advanced gastric cancer
Is Satri-Cel CAR T Therapy Right for You or Your Loved One?
Satri-Cel CAR T Therapy may be a highly effective option for patients with the following criteria:
✅ Advanced gastric or GEJ cancer
✅ Positive Claudin 18.2 expression in biopsy samples
✅ Disease progression after standard treatments
CancerFax: Your Gateway to Leading CAR T Centers in China
If you’re seeking access to the best CAR T therapy centers in China, chinamedtours.com can help connect you to top hospitals and leading
specialists in this field.
Satri-Cel CAR T Therapy has proven that cell-based immunotherapies are no longer limited to hematologic malignancies. The remarkable results from ASCO 2025 signal a new era for the treatment of gastric and GEJ cancers.
Now, with direct patient access to leading hospitals in China, this revolutionary treatment is becoming a real-world option for patients worldwide.
